ImmunityBio gets hit with a class action grenade

Lawsuit season, now featuring biotech

ImmunityBio is back in the spotlight, and not for the reason anyone in the cap table wanted. The Portnoy Law Firm says it’s filing a class action on behalf of investors who bought shares during the alleged class period, putting the company squarely in litigation-land.

Why this matters

The complaint is tied to the fallout from ImmunityBio’s January 23 disclosure about updated Phase 2 clinical results for its glioblastoma program. In plain English: investors were already spooked by the trial update, and now the legal system is joining the party.

The biotech two-step

Here’s the annoying part for shareholders:

• The lawsuit focuses on the market drop after the clinical update
• The company’s QUILT 3.078 trial is central to the drama
• The headline issue is that median overall survival, the primary endpoint, had not yet been reached

That kind of phrasing can sound like biotech code, but the market hears it loud and clear: uncertainty, no clean win yet, and a reason for traders to keep one foot near the exit.

Big picture

This doesn’t magically rewrite the science, but it does add another layer of risk around the stock. For a biotech like ImmunityBio, legal headlines can hang around like a stubborn plot twist — not fatal on their own, but definitely not helping the mood.